Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic versus autologous serum eye drops in severe dry eye disease
NL-OMON44085Active, not recruiting
- Sponsor
- Sanquin
- Start
- Jun 2017
- Modality
- Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Randomised, double-blind trial of autologous serum artificial tears and allogenic serum in dry eye syndrome (DED) and Corneal lesion (2 arms), sponsored by Sanquin. Primary endpoint: Ocular Surface Disease Index score. Started Jun 2017; status: active, not recruiting.
02
Drugs
autologous serum artificial tearsallogenic serum
03
Conditions
dry eye syndrome (DED)Corneal lesion
Beyond the preview
Go deeper on NL-OMON44085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44085.